Boehringer begins enrolment in Phase II trial of BI 655064 to treat lupus nephritis

Pharmaceutical company Boehringer Ingelheim has begun patient enrolment in the Phase II clinical trial of BI 655064 for the treatment of lupus nephritis (LN).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news